Global News Aggregator
Check out the companies making headlines in extended trading: Palantir Technologies — Shares declined nearly 5% after the company issued lighter-than-expected guidance for full-year revenue. First-quarter adjusted earnings were in…
The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of…
Check out the companies making headlines after hours. Palantir Technologies — Shares jumped 17% after Palantir posted a revenue beat in the fourth quarter. Revenue came in at $608.4 million…
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Brian Snyder | Reuters Vertex Pharmaceuticals on Tuesday said its experimental painkiller,…
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Brian Snyder | Reuters Shares of Vertex Pharmaceuticals jumped Wednesday after the…
The U.S. Food and Drug Administration on Friday approved the country’s first gene-editing treatment, Casgevy, for use in patients with sickle cell disease. The approval comes about a decade after…
At age 19, Joe Tsogbe underwent his first hip replacement. In his 20s, he averaged about nine hospitalizations a year. By his 30s, that rose to more than a dozen.…
CNBC’s Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid.…
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically,…
A Walgreens store is seen on August 07, 2019 in Miami, Florida. Joe Raedle | Getty Images Check out the companies making headlines in midday trading. Doximity — The online…